Procedures | Data | Screening | Baseline | Treatment phase | Event based | |
---|---|---|---|---|---|---|
 | Face-to-face visit 1 | Follow-up (min = 32 month, max = 91 months) No visits | ||||
Linkage | Patient questionnaire (6 monthly) | |||||
Eligibility assessment |  | √ |  |  |  |  |
Informed consent |  |  | √ |  |  |  |
Randomisation |  |  | √ |  |  |  |
Demographics | Age, sex, ethnicity, marital status, education level, smoking history |  | √ |  |  |  |
Clinical (1) | Primary renal disease, date first seen by a nephrologist, co-morbidities, dietary restrictions, 24-h urine volume |  | √ |  |  |  |
Clinical (2) | RRT treatment history, prescribed medication (including erythropoiesis-stimulating agents and phosphate binders) |  | √ | √ |  |  |
Physical assessment (1) | Height, heart rate |  | √ |  |  |  |
Physical assessment (2) | Weight, systolic and diastolic blood pressure |  | √ | √ |  |  |
Resource use (1) | Day case and inpatient hospital admissions (including surgical procedures performed) |  | √ | √ |  |  |
Resource use (2) | Nursing home/residential home days/hospice days, other hospital out-patient services and primary care and community services in the last 6 months |  | √ |  | √ |  |
Laboratory tests | Creatinine, urea, Kt/V, urea reduction ratio, albumin, haemoglobin, haematocrit, mean corpuscular volume, sodium, potassium, bicarbonate, corrected calcium, phosphate, C-reactive protein, intact parathyroid hormone, total cholesterol. (From the date of the study visit or the closest date prior to the study visit) |  | √ | √ |  |  |
Patient reported | EQ-5D-5L and DSI and time to recovery [31] |  | √ |  | √ |  |
SAE reporting |  |  |  |  |  | √ |